These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 39321707)

  • 21. Use of long-term corticosteroids in patients treated with CAR T-cell therapy.
    Hashmi H; McGann M; Greenwell BI
    J Oncol Pharm Pract; 2023 Mar; 29(2):473-476. PubMed ID: 35635259
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Severe persistent neurotoxicity associated with CAR T therapy in children.
    Andrew EC; Hughes D; Gilsenan M; Mignone C; Khaw SL; Wang SS
    Br J Haematol; 2023 Nov; 203(4):651-655. PubMed ID: 37528536
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy.
    Sterner RC; Sterner RM
    Front Immunol; 2022; 13():879608. PubMed ID: 36081506
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CAR-T Cell Therapy-Related Neurotoxicity in Pediatric Acute Lymphoblastic Leukemia: Spectrum of Imaging Findings.
    Tan AP
    Pediatr Neurol; 2020 Oct; 111():51-58. PubMed ID: 32951662
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results.
    Park JH; Nath K; Devlin SM; Sauter CS; Palomba ML; Shah G; Dahi P; Lin RJ; Scordo M; Perales MA; Shouval R; Tomas AA; Cathcart E; Mead E; Santomasso B; Holodny A; Brentjens RJ; Riviere I; Sadelain M
    Nat Med; 2023 Jul; 29(7):1710-1717. PubMed ID: 37400640
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multifocal demyelinating leukoencephalopathy and oligodendroglial lineage cell loss with immune effector cell-associated neurotoxicity syndrome (ICANS) following CD19 CAR T-cell therapy for mantle cell lymphoma.
    Nie EH; Ahmadian SS; Bharadwaj SN; Acosta-Alvarez L; Threlkeld ZD; Frank MJ; Miklos DB; Monje M; Scott BJ; Vogel H
    J Neuropathol Exp Neurol; 2023 Jan; 82(2):160-168. PubMed ID: 36592076
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical features of neurotoxicity after CD19 CAR T-cell therapy in mantle cell lymphoma.
    Nie EH; Su YJ; Baird JH; Agarwal N; Bharadwaj S; Weng WK; Smith M; Dahiya S; Han MH; Dunn JE; Kipp LB; Miklos DB; Scott BJ; Frank MJ
    Blood Adv; 2024 Mar; 8(6):1474-1486. PubMed ID: 38295285
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19.
    Diorio C; Shraim R; Myers R; Behrens EM; Canna S; Bassiri H; Aplenc R; Burudpakdee C; Chen F; DiNofia AM; Gill S; Gonzalez V; Lambert MP; Leahy AB; Levine BL; Lindell RB; Maude SL; Melenhorst JJ; Newman H; Perazzelli J; Seif AE; Lacey SF; June CH; Barrett DM; Grupp SA; Teachey DT
    Clin Cancer Res; 2022 Sep; 28(17):3804-3813. PubMed ID: 35705524
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study.
    Azoulay É; Castro P; Maamar A; Metaxa V; de Moraes AG; Voigt L; Wallet F; Klouche K; Picard M; Moreau AS; Van De Louw A; Seguin A; Mokart D; Chawla S; Leroy J; Böll B; Issa N; Levy B; Hemelaar P; Fernandez S; Munshi L; Bauer P; Schellongowski P; Joannidis M; Moreno-Gonzalez G; Galstian G; Darmon M; Valade S;
    Lancet Haematol; 2021 May; 8(5):e355-e364. PubMed ID: 33894170
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current and emerging pharmacotherapies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis-like syndrome due to CAR T cell therapy.
    Walton ZE; Frigault MJ; Maus MV
    Expert Opin Pharmacother; 2024 Feb; 25(3):263-279. PubMed ID: 38588525
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL.
    Sheth VS; Gauthier J
    Bone Marrow Transplant; 2021 Mar; 56(3):552-566. PubMed ID: 33230186
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
    Caimi PF; Pacheco Sanchez G; Sharma A; Otegbeye F; Ahmed N; Rojas P; Patel S; Kleinsorge Block S; Schiavone J; Zamborsky K; Boughan K; Hillian A; Reese-Koc J; Maschan M; Dropulic B; Sekaly RP; de Lima M
    Front Immunol; 2021; 12():745320. PubMed ID: 34712233
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Concise Review of Neurologic Complications Associated with Chimeric Antigen Receptor T-cell Immunotherapy.
    Ruff MW; Siegler EL; Kenderian SS
    Neurol Clin; 2020 Nov; 38(4):953-963. PubMed ID: 33040871
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Long-term follow-up of humanized and murine CD19 CAR-T-cell therapy for B-cell acute lymphoblastic leukemia].
    Du MY; Zhang YQ; Liao DY; Xie W; Xiong W; Mei H; Hu Y
    Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):793-799. PubMed ID: 38049329
    [No Abstract]   [Full Text] [Related]  

  • 35. Frontal Intermittent Rhythmic Delta Activity Is a Useful Diagnostic Tool of Neurotoxicity After CAR T-Cell Infusion.
    Huby S; Gelisse P; Tudesq JJ; Labauge P; Duflos C; Cartron G; Gallerand MA; Platon L; Badiou S; Lamure S; Menjot de Champfleur N; Ayrignac X; Taieb G
    Neurol Neuroimmunol Neuroinflamm; 2023 Jul; 10(4):. PubMed ID: 37059470
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Forecasting immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor t-cell therapy.
    Amidi Y; Eckhardt CA; Quadri SA; Malik P; Firme MS; Jones DK; Jain A; Danish HH; Rubin DB; Jacobson CA; Cash SS; Lee JW; Dietrich J; Westover MB
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36450377
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of Neurotoxicity after Chimeric Antigen Receptor (CAR) T Cell Infusion without Deterioration in the Immune Effector Cell Encephalopathy (ICE) Score.
    Herr MM; Chen GL; Ross M; Jacobson H; McKenzie R; Markel L; Balderman SR; Ho CM; Hahn T; McCarthy PL
    Biol Blood Marrow Transplant; 2020 Nov; 26(11):e271-e274. PubMed ID: 32736009
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neurological management and work-up of neurotoxicity associated with CAR T cell therapy.
    Möhn N; Bonda V; Grote-Levi L; Panagiota V; Fröhlich T; Schultze-Florey C; Wattjes MP; Beutel G; Eder M; David S; Körner S; Höglinger G; Stangel M; Ganser A; Koenecke C; Skripuletz T
    Neurol Res Pract; 2022 Jan; 4(1):1. PubMed ID: 35000613
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neurotoxicity Biology and Management.
    Danish H; Santomasso BD
    Cancer J; 2021 Mar-Apr 01; 27(2):126-133. PubMed ID: 33750072
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peripheral blood cellular profile at pre-lymphodepletion is associated with CD19-targeted CAR-T cell-associated neurotoxicity.
    De Matteis S; Dicataldo M; Casadei B; Storci G; Laprovitera N; Arpinati M; Maffini E; Cortelli P; Guarino M; Vaglio F; Naddeo M; Sinigaglia B; Zazzeroni L; Guadagnuolo S; Tomassini E; Bertuccio SN; Messelodi D; Ferracin M; Bonafè M; Zinzani PL; Bonifazi F
    Front Immunol; 2022; 13():1058126. PubMed ID: 36726971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.